Key points are not available for this paper at this time.
Figure S12. Mean usage of stromal cNMF programs per stromal cell subset at (A) baseline, (B) post-chemotherapy (FU1) and (C) post-immunotherapy (FU2).
Share your take
Add a clinician perspective alongside expert commentary.
An et al. (Wed,) studied this question.